Partial
Partially Aligned
Patient Risk:
Unknown
Summary
Supported label alignment for indications and core ARB mechanism, but multiple claims (tablet inactive ingredients, “heart workload,” and comparative/other-drug examples) are not supported by the provided label text, and key safety sections cannot be verified from the provided claim set.
Category Scores
Accurate Statements
The active ingredient in valsartan is valsartan.
Label 12.1 references “Diovan (valsartan)” indicating valsartan is the drug substance.
Valsartan is a medication prescribed to treat high blood pressure.
Label 1.1 indicates Diovan is indicated to treat hypertension.
Valsartan is a medication prescribed to treat heart failure.
Label 1.2 indicates Diovan reduces risk of hospitalization for heart failure in adults (NYHA II-IV).
Valsartan is an angiotensin II receptor blocker (ARB).
Label 12.1 describes selective blocking of angiotensin II binding to the AT1 receptor.
Valsartan works by blocking the action of angiotensin II.
Label 12.1 states valsartan blocks vasoconstrictor and aldosterone-secreting effects of angiotensin II.
Valsartan belongs to the ARB class of drugs.
Implied by Label 12.1 AT1 receptor blockade of angiotensin II.
Each class of blood pressure medications works through different mechanisms to lower blood pressure.
Label 1.1 states antihypertensive drugs have different mechanisms of action across pharmacologic classes.
Unsupported Statements
Valsartan tablets contain inactive ingredients including microcrystalline cellulose.
No inactive ingredient list provided in the available label excerpts.
Valsartan tablets contain inactive ingredients including povidone.
No inactive ingredient list provided in the available label excerpts.
Valsartan tablets contain inactive ingredients including crospovidone.
No inactive ingredient list provided in the available label excerpts.
Valsartan tablets contain inactive ingredients including colloidal anhydrous silica.
No inactive ingredient list provided in the available label excerpts.
Valsartan tablets contain inactive ingredients including magnesium stearate.
No inactive ingredient list provided in the available label excerpts.
Valsartan reduces the workload on the heart.
No such claim appears in the provided label excerpts.
Other ARBs available that work similarly to valsartan include losartan.
No comparative/other-ARB examples appear in the provided label excerpts.
Other ARBs available that work similarly to valsartan include olmesartan.
No comparative/other-ARB examples appear in the provided label excerpts.
Other ARBs available that work similarly to valsartan include candesartan.
No comparative/other-ARB examples appear in the provided label excerpts.
Other ARBs are often prescribed for the same conditions as valsartan.
No such prescribing-frequency statement appears in the provided label excerpts.
Other classes of blood pressure medications include ACE inhibitors (e.g., lisinopril).
Label 1.1 discusses different classes but the provided excerpt does not name lisinopril.
Other classes of blood pressure medications include calcium channel blockers (e.g., amlodipine).
Label 1.1 discusses different classes but the provided excerpt does not name amlodipine.
Other classes of blood pressure medications include diuretics (e.g., hydrochlorothiazide).
Label 1.1 discusses different classes but the provided excerpt does not name hydrochlorothiazide.
Contradictions
Important Omissions
No evaluation of boxed warnings, contraindications, dosing/administration, drug interactions, adverse reactions, or monitoring because none were included in the provided claim set.
Importance:
High
Safety Assessment
Potential Patient Risk:
Unknown
The claim set does not include safety-critical label elements (boxed warnings, contraindications, dosing/administration, drug interactions, adverse reactions, monitoring). Therefore, label compliance for these areas cannot be confirmed from the provided content.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are not supported by the provided label excerpts, including inactive ingredient composition, comparative/other-drug examples, and an efficacy/mechanism statement (“reduces the workload on the heart”). Safety sections were not evaluable from the provided claims.
Suggested Improvement
Limit claims to label-supported content in the provided sections (Indications 1.1/1.2 and Mechanism of Action 12.1), remove inactive-ingredient and comparative drug-class examples unless the corresponding label sections are provided, and evaluate/add safety-critical label content (boxed warnings/contraindications/dosing/interactions/AE/monitoring) before making comprehensive compliance statements.